Sector: MedicalNektar Therapeutics (NASDAQ: NKTR)
Ranking History
Scan Date: | 11/10/2009 |
Sector: | Medical |
Funamental : | 124 |
Technical : | 146 |
Performance : | 150 |
Overall: | 138 |
Number of Stocks: | 306 |
Scan Date: | 11/3/2009 |
Sector: | Medical |
Funamental : | 163 |
Technical : | 287 |
Performance : | 227 |
Overall: | 273 |
Number of Stocks: | 306 |
Scan Date: | 10/27/2009 |
Sector: | Medical |
Funamental : | 156 |
Technical : | 185 |
Performance : | 189 |
Overall: | 210 |
Number of Stocks: | 306 |
Headlines
- Diabetes Care: Global Investing Opportunities
Nov 22, 2009 11:28 PM | ABT, ACCP, ALKS, AMLN, ASX, BDX
- Nektar Therapeutics Reports Third Quarter 2009 Financial Results
Nov 04, 2009 04:15 PM | NKTR
- Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets
Oct 29, 2009 05:28 PM | NKTR
- Alexandria Real Estate Equities, Inc. Provides Update
Oct 29, 2009 08:31 AM | ARE, NKTR, PFE
- The F.I.R.S.T. System: Searching For The 'Holy Grail' Of Investing
Oct 28, 2009 01:01 PM | NKTR
- Nektar Completes Enrollment Ahead of Schedule in Phase 2 Clinical Trial Evaluating NKTR-102 in Patients with Platinum-Resistant Ovarian Cancer
Oct 28, 2009 06:40 AM | NKTR
- Phase 2 Data From Oral NKTR-118 Presented at American College of Gastroenterology in San Diego
Oct 27, 2009 12:35 PM | NKTR
- Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix
Oct 10, 2009 07:00 PM | NKTR
- NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
Sep 22, 2009 08:03 AM | NKTR
- Nektar Therapeutics to Host Conference Call to Discuss Today's Announcement of a New Partnership for NKTR-118 and NKTR-119
Sep 21, 2009 07:01 AM | NKTR
- AstraZeneca: Third Quarter and Nine Months Results 2009
Oct 29, 2009 09:57 AM | AZN, FRX, NKTR
- Nektar Therapeutics Reports Second Quarter 2009 Financial Results
Aug 04, 2009 04:54 PM | AMGN, NKTR
- West Announces Second Quarter 2009 Results ; - Adjusted Diluted EPS (1) of $0.58 -; - Revises Adjusted Diluted EPS(1) Estimate to Between $2.10 and $2.20 -; - Conference Call Scheduled for 9 A.M. Today -
Aug 04, 2009 01:50 PM | NKTR, PFE, WST
- Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
Jul 31, 2009 03:51 PM | NKTR
- Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets
Jul 31, 2009 02:26 PM | NKTR
- Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
Jun 09, 2009 09:03 AM | NKTR
- Nektar Announces UCB's Cimzia(R) Approved by U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
May 14, 2009 09:47 AM | NKTR
- Nektar Therapeutics to Present at the Deutsche Bank 34th Annual Health Care Conference in Boston
May 12, 2009 04:16 PM | NKTR
- Nektar Therapeutics Reports First Quarter 2009 Financial Results
May 06, 2009 04:52 PM | NKTR
- Nektar to Announce Financial Results for the First Quarter of 2009 on Wednesday, May 6, 2009, After Close of U.S.-Based Financial Markets
Apr 29, 2009 08:51 PM | NKTR
- Form 4 NEKTAR THERAPEUTICS For: Nov 18 Filed by: Labrucherie Gil M (10K)
Nov 20, 2009 02:47 PM
- Form 4 NEKTAR THERAPEUTICS For: Nov 18 Filed by: Nicholson John (10K)
Nov 20, 2009 02:45 PM
- Form 4 NEKTAR THERAPEUTICS For: Nov 18 Filed by: CHOWRIRA BHARAT M (10K)
Nov 20, 2009 02:42 PM
- Form 4/A WANG SUSAN For: Sep 15 (10K)
Sep 22, 2009 02:40 PM
- Form 4/A CHESS ROBERT For: Sep 15 (10K)
Sep 22, 2009 02:22 PM
- Form 4 KUEBLER CHRISTOPHER A For: Sep 15 (10K)
Sep 17, 2009 07:50 PM
- Form 4 Krivulka Joseph J For: Sep 15 (10K)
Sep 17, 2009 07:49 PM
- Form 4 Lingnau Lutz For: Sep 15 (10K)
Sep 17, 2009 07:47 PM
- Form 4 BROWN MICHAEL A/CA For: Sep 15 (10K)
Sep 17, 2009 07:46 PM
- Form 4 CHESS ROBERT For: Sep 15 (10K)
Sep 17, 2009 07:44 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
NKTR
|
Compare to S&P
|
| YTD |
55.40 %
|
28.61 %
|
| 4 Weeks |
-4.74 %
|
-5.77 %
|
| 12 Weeks |
6.01 %
|
-0.05 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 5.71 %
|
|
EPS Growth in Last Year: 17.50 %
|
|
Sales Growth in Last Quarter: -21.29 %
|
|
Sales Growth in Last Quarter: -52.32 %
|
|
